These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32939993)

  • 41. Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas.
    Lin RL; Wang TJ; Joyce CJ; Mihm MC; Murphy GF; Lian CG; Lin JY
    Melanoma Res; 2016 Oct; 26(5):524-7. PubMed ID: 26974966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF.
    Si Z; Hersey P; Coates AS
    Melanoma Res; 1996 Jun; 6(3):247-55. PubMed ID: 8819128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma.
    Vasaturo A; Di Blasio S; Verweij D; Blokx WA; van Krieken JH; de Vries IJ; Figdor CG
    Histopathology; 2017 Mar; 70(4):643-649. PubMed ID: 27571246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy of malignant melanoma.
    Oratz R; Bystryn JC
    Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer.
    Liu Y; Liu Z; Yang Y; Cui J; Sun J; Liu Y
    Br J Cancer; 2023 Oct; 129(7):1041-1049. PubMed ID: 37452117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy of advanced or metastatic melanoma.
    Cebon J; Gedye C; John T; Davis ID
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
    Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
    Front Immunol; 2021; 12():629519. PubMed ID: 33746966
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Future of malignant stage I melanoma. Immunology and immunotherapy].
    Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP
    Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476
    [No Abstract]   [Full Text] [Related]  

  • 50. Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight.
    Hussein MR
    Br J Dermatol; 2005 Jul; 153(1):18-21. PubMed ID: 16029321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melanoma-induced immunosuppression and its neutralization.
    Umansky V; Sevko A
    Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of immune activation and regulation: lessons from melanoma.
    Kalaora S; Nagler A; Wargo JA; Samuels Y
    Nat Rev Cancer; 2022 Apr; 22(4):195-207. PubMed ID: 35105962
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
    Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
    Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.
    Fortes C; Mastroeni S; Mannooranparampil TJ; Passarelli F; Zappalà A; Annessi G; Marino C; Caggiati A; Russo N; Michelozzi P
    Melanoma Res; 2015 Aug; 25(4):306-11. PubMed ID: 25933208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.
    Punt S; Malu S; McKenzie JA; Manrique SZ; Doorduijn EM; Mbofung RM; Williams L; Silverman DA; Ashkin EL; Dominguez AL; Wang Z; Chen JQ; Maiti SN; Tieu TN; Liu C; Xu C; Forget MA; Haymaker C; Khalili JS; Satani N; Muller F; Cooper LJN; Overwijk WW; Amaria RN; Bernatchez C; Heffernan TP; Peng W; Roszik J; Hwu P
    Cancer Immunol Immunother; 2021 Apr; 70(4):1101-1113. PubMed ID: 33123754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant immunotherapy for melanoma.
    Thomas D; Bello DM
    J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
    Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
    Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
    J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes.
    Su Y; Jackson EK; Gorelik E
    Cancer Immunol Immunother; 2011 Jan; 60(1):111-22. PubMed ID: 20960188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
    León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
    J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.